Abstract
Acetylcholinesterase (AChE) is an attractive target of drugs for Alzheimer’s disease (AD). A series of novel synthesized flavonoid derivatives have been reported as potent AChE inhibitors, but the lack of structure-AChE inhibitory activity relationships hampers the design of specific and selective flavonoid derivatives. In this study, 3D-quantitative structure activity relationship (3D-QSAR) models of 90 flavonoid derivatives as AChE inhibitors were established by using CoMFA and CoMSIA techniques. The results showed that both CoMFA model (q2= 0.651, r2= 0.939, F value = 173.5 and SEE=0.218 ) and CoMSIA model (q2= 0.680, r2= 0.947, F value = 151.8 and SEE=0.226) demonstrated statistically significant results and good predictive ability. Furthermore, docking studies were used for better understanding of the binding modes between flavonoid inhibitors and AChE. In conclusion, the essential information obtained from this study could provide valuable insight for further modification of highly potent AChE inhibitors.
Keywords: AChE inhibitors, flavonoid derivatives, 3D-QSAR, CoMFA, CoMSIA, molecular docking.
Letters in Drug Design & Discovery
Title:3D-QSAR and Molecular Docking Studies of Flavonoid Derivatives as Potent Acetylcholinesterase Inhibitors
Volume: 12 Issue: 10
Author(s): An Zhou, Zeyu Wu, Ailing Hui, Bin Wang, Xianchun Duan, Haixiang Wang and Jian Pan
Affiliation:
Keywords: AChE inhibitors, flavonoid derivatives, 3D-QSAR, CoMFA, CoMSIA, molecular docking.
Abstract: Acetylcholinesterase (AChE) is an attractive target of drugs for Alzheimer’s disease (AD). A series of novel synthesized flavonoid derivatives have been reported as potent AChE inhibitors, but the lack of structure-AChE inhibitory activity relationships hampers the design of specific and selective flavonoid derivatives. In this study, 3D-quantitative structure activity relationship (3D-QSAR) models of 90 flavonoid derivatives as AChE inhibitors were established by using CoMFA and CoMSIA techniques. The results showed that both CoMFA model (q2= 0.651, r2= 0.939, F value = 173.5 and SEE=0.218 ) and CoMSIA model (q2= 0.680, r2= 0.947, F value = 151.8 and SEE=0.226) demonstrated statistically significant results and good predictive ability. Furthermore, docking studies were used for better understanding of the binding modes between flavonoid inhibitors and AChE. In conclusion, the essential information obtained from this study could provide valuable insight for further modification of highly potent AChE inhibitors.
Export Options
About this article
Cite this article as:
Zhou An, Wu Zeyu, Hui Ailing, Wang Bin, Duan Xianchun, Wang Haixiang and Pan Jian, 3D-QSAR and Molecular Docking Studies of Flavonoid Derivatives as Potent Acetylcholinesterase Inhibitors, Letters in Drug Design & Discovery 2015; 12 (10) . https://dx.doi.org/10.2174/1570180812666150514233543
DOI https://dx.doi.org/10.2174/1570180812666150514233543 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways
Current Pharmaceutical Design Harnessing Anesthesia and Brain Imaging for the Study of Human Consciousness
Current Pharmaceutical Design The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Current Neuropharmacology Past and Recent Progress of Molecular Imaging Probes for β-Amyloid Plaques in the Brain
Current Medicinal Chemistry Hypopituitarism in Neurocritical Patients: A Case Report
Endocrine, Metabolic & Immune Disorders - Drug Targets A Co-Module Regulated by Therapeutic Drugs in a Molecular Subnetwork of Alzheimer’s Disease Identified on the Basis of Traditional Chinese Medicine and SAMP8 Mice
Current Alzheimer Research Multivariate Optimization Model in a Partial Least Squares-1 Method for Simultaneous Determination of Dorzolamide Hydrochloride and Timolol Maleate in Eye Drops
Current Pharmaceutical Analysis Therapeutic Agents for Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias
Current Neuropharmacology Mental Training for Cognitive Improvement in Elderly People: What have We Learned from Clinical and Neurophysiologic Studies?
Current Alzheimer Research Frontotemporal Dementia Caused by CHMP2B Mutations
Current Alzheimer Research Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
Current Medicinal Chemistry Diagnosis and Treatment of Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Semicarbazide-Sensitive Amine Oxidase: Current Status and Perspectives
Current Medicinal Chemistry Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design